Compare ADAM & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADAM | ARDX |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 702.0M | 797.8M |
| IPO Year | 2003 | 2014 |
| Metric | ADAM | ARDX |
|---|---|---|
| Price | $6.01 | $3.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $11.50 | ★ $12.80 |
| AVG Volume (30 Days) | 1.0M | ★ 4.3M |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | ★ 18.35% | N/A |
| EPS Growth | ★ 196.49 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | N/A | $19.21 |
| Revenue Next Year | $8.59 | $28.19 |
| P/E Ratio | $7.53 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.55 | $2.96 |
| 52 Week High | $10.36 | $8.40 |
| Indicator | ADAM | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 19.31 | 37.18 |
| Support Level | N/A | N/A |
| Resistance Level | $9.36 | $3.35 |
| Average True Range (ATR) | 0.31 | 0.13 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 5.00 | 15.19 |
Adamas Trust Inc is an internally-managed REIT for U.S. federal income tax purposes, in the business of acquiring, investing in, financing, and managing mainly mortgage-related single-family and multi-family residential assets. Its objective is to deliver long-term stable distributions to its stockholders over changing economic conditions through a combination of net interest spread and capital gains from a diversified investment portfolio. The company's investment portfolio includes credit-sensitive single-family and multi-family assets.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.